Skip to main content

Lung

Protocols

Non-Small Cell Lung Cancer (Adjuvant)

ULUAJATZ

Adjuvant Treatment of Resected Non-Small Cell Lung Cancer using Atezolizumab


LUAJNIVPC

Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab, CARBOplatin and PACLitaxel


LUAJNIVPP

Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab, Pemetrexed and Platinum


LUAJNP

Adjuvant CISplatin and vinorelbine following resection of non-small cell lung cancer


LUAJOSI

Adjuvant Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) with Osimertinib


LUAJPC

Adjuvant CARBOplatin and PACLitaxel following resection of stage I, II and IIIA non-small cell lung cancer


LUAJPP

Adjuvant CISplatin and Pemetrexed Following Resection of Non-Small Cell Lung Cancer


LULADUR

Locally Advanced Non-Small Cell Lung Cancer Using Durvalumab


LULADUR4

Treatment of Locally Advanced Non-Small Cell Lung Cancer Using 4-Weekly Durvalumab

Top

Non-Small Cell Lung Cancer (Advanced)

Targeted Therapy

LUAVAFAT

First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Afatinib


LUAVALE

Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Alectinib


LUAVBRI

First-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Brigatinib


LUAVCER

Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Ceritinib


LUAVCRIZ

Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib


LUAVCRIZF

First-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib


LUAVCRIZR

First-Line Treatment of ROS1-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib


LUAVENT

First-Line Treatment of ROS1-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Entrectinib


LUAVERL

Second- or Later-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Erlotinib


LUAVGEFF

First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Gefitinib


LUAVLOR

Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Lorlatinib


LUAVMTNE

Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) with Erlotinib After First-Line Chemotherapy


LUAVOSI

Treatment of EGFR T790M Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Osimertinib


LUAVOSIF

First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Osimertinib


LUAVSEL

Treatment of RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Selpercatinib


Immunotherapy

LUAVATZ

Treatment of Advanced Non-Small Cell Lung Cancer Using Atezolizumab


LUAVATZ4

Treatment of Advanced Non-Small Cell Lung Cancer Using 4-Weekly Atezolizumab


LUAVNIV

Treatment of Advanced Non-Small Cell Lung Cancer Using Nivolumab


LUAVNIV4

Treatment of Advanced Non-Small Cell Lung Cancer Using 4-Weekly Nivolumab


LUAVPCIPNI

First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with PACLitaxel, CARBOplatin, Ipilimumab and Nivolumab


 

LUAVPCPMB

First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with PACLitaxel, CARBOplatin and Pembrolizumab


LUAVPGPMB

First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Platinum, Gemcitabine and Pembrolizumab


LUAVPMB

Treatment of Advanced Non-Small Cell Lung Cancer Using Pembrolizumab


LUAVPMB6

Treatment of Advanced Non-Small Cell Lung Cancer Using 6-Weekly Pembrolizumab


LUAVPMBM

Maintenance Therapy of Advanced Non-Small Cell Lung Cancer with Pembrolizumab


LUAVPMBM6

Maintenance Therapy of Advanced Non-Small Cell Lung Cancer with 6-Weekly Pembrolizumab


LUAVPPIPNI

First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab

LUAVPPMBM

Maintenance Therapy of Advanced Non-Squamous Non-Small Cell Lung Cancer with Pemetrexed and Pembrolizumab


LUAVPPPMB

First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed and Pembrolizumab


LUAVPMBF

First-Line Treatment of Advanced Non-Small Cell Lung Cancer Using Pembrolizumab


LUAVPMBF6

First-Line Treatment of Advanced Non-Small Cell Lung Cancer Using 6-Weekly Pembrolizumab


Chemotherapy

LUAVDC

First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with CISplatin and DOCEtaxel


LUAVDOC

Second or Later-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with DOCEtaxel


LUAVNP

Treatment for advanced non-small cell lung cancer (NSCLC) with CISplatin and vinorelbine


LUAVPC

First-Line treatment of advanced non-small cell lung cancer (NSCLC) with CARBOplatin and PACLitaxel


LUAVPEM

Second-Line Chemotherapy of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pemetrexed


LUAVPG

Treatment of advanced non-small cell lung cancer (NSCLC) with platinum and gemcitabine


LUAVPMTN

Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pemetrexed


LUAVPP

First-Line Treatment of Advanced Non-Small Cell Lung Cancer With Platinum and Pemetrexed


LUAVVIN

Treatment of advanced non-small cell lung cancer (NSCLC) with vinorelbine in elderly patients

Top

Non-Small Cell Lung Cancer (Combined Modality Therapy)

LULACATRT

Treatment of Locally Advanced Non-Small Cell Lung Cancer using CARBOplatin and PACLitaxel with Radiation Therapy


LULAPE2RT

Treatment of locally advanced non-small cell lung cancer using Alternative Dosing of CISplatin and etoposide with radiation therapy


LULAPERT

Treatment of locally advanced non-small cell lung cancer using CISplatin and etoposide with radiation therapy

Small Cell Lung Cancer (Limited Stage)

LUSCPEPORT

Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Oral Etoposide with Radiation Therapy


LUSCPERT

Therapy of limited stage small cell lung cancer using CISplatin and etoposide with radiation

Small Cell Lung Cancer (Extensive Stage)

LUSCATPE

Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Atezolizumab, Platinum and Etoposide


LUSCCAV

Treatment of Extensive Small Cell Lung Cancer (SCLC) with Cyclophosphamide, DOXOrubicin and vinCRIstine (CAV)


LUSCDURPE

Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Durvalumab, Platinum and Etoposide


LUSCPE

Therapy of extensive stage small cell lung cancer (SCLC) with CISplatin and etoposide


LUSCPEPO

Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Platinum and Oral Etoposide


LUSCPI

Second-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Irinotecan With or Without Platinum


LUSCPOE

Palliative therapy of extensive stage small cell lung cancer (SCLC) with oral Etoposide


LUSCTOP

Second line treatment of recurrent small cell lung cancer (SCLC) with topotecan

Top

Malignant Mesothelioma

LUMMIPNI

Treatment of Malignant Mesothelioma using Ipilimumab and Nivolumab


LUMMIPNI3

Treatment of Malignant Mesothelioma using Ipilimumab and 3-Weekly Nivolumab


LUMMPG

Treatment of malignant mesothelioma with platinum and gemcitabine


LUMMPP

Treatment of Malignant Mesothelioma with Platinum and Pemetrexed


LUMMVIN

Treatment of Malignant Mesothelioma with Vinorelbine

Top

Other Thoracic Malignancies

LUNETEV

Treatment of Advanced Neuroendocrine Tumours of Lung Origin (Non-Functional) Using Everolimus


LUOTCAV

Treatment of Thymoma/Thymic Carcinoma with Cyclophosphamide, DOXOrubicin and vinCRIstine (CAV)


LUOTPAC

Treatment of Thymoma with Platinum, DOXOrubicin and Cyclophosphamide


LUOTPE

Treatment of thymoma with CISplatin and etoposide


LUOTPERT

Treatment of thymoma using CISplatin and etoposide with radiation therapy


LUPUPE

Treatment of Cancer of Unknown Primary Involving the Thorax with CISplatin and etoposide

Funding Algorithm

The funding algorithm provides information on what anti-cancer systemic therapy treatments are covered on the BC Cancer Benefit Drug List (formulary). It may not be a complete list of all treatment options that may be available and recommended by the treating physician.

Terms of use

The information contained in these documents is a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer's Terms of Use.

Tab Heading
SOURCE: Lung ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2024 Provincial Health Services Authority